Cardiovascular disease: risk assessment and reduction, including lipid modification: call for evidence
We are listening to your views on this NICE guideline. Comments close 22 July 2022.
Search results
12 results
-
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
MRI-based technologies for assessing non-alcoholic fatty liver disease: diagnostics consultation
We are listening to your views on this Diagnostics guidance. Comments close 14 July 2022.
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Thyroid cancer: assessment and management: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 4 August 2022.
-
Advocacy services for adults with health and social care needs: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 19 July 2022.
-
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis [ID3787]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2022.
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Advocacy services for adults with health and social care needs: draft scope consultation
We are listening to your views on this NICE guideline. Comments close 22 January 2021.
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 20 July 2022.